Creating capsules of ammonium tetrathiomolibdate for clinical use
Official title: PRODUCTION OF AMMONIUM TETRATHIOMOLIBDATE (ATTM) CAPSULES FOR USE IN CLINICAL TRIALS
Funded at Irisys, INC. · NIH-10710311 · Data updated 2026-11-12
This study is working on creating special capsules that contain a new treatment for patients, and it aims to make sure these capsules are safe and effective for future clinical trials.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Irisys, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | March 8, 2022 |
| Project end | March 7, 2026 |
| Funding year | 2022 |
| Award (this year) | $413,130 |
| NIH project number | 75N98019D00058-0-759102200002-1 |
| Project ID | NIH-10710311 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would be individuals who are eligible for clinical trials involving ammonium tetrathiomolibdate.
✕Less likely to help
Patients who are not eligible for clinical trials or those who do not have conditions that could be treated with ATTM may not benefit from this research.
What this research studies
This research focuses on producing ammonium tetrathiomolibdate (ATTM) capsules that will be used in clinical trials. The project involves engineering a batch of these capsules, ensuring they meet current Good Manufacturing Practices (cGMP), and conducting studies on their delivery and shelf-life. Patients may benefit from this research as it aims to develop a new treatment option that could be tested in future clinical trials. The methodology includes rigorous production processes and quality assessments to ensure the capsules are safe and effective for patient use.
Why it matters
Potential benefit: If successful, this research could provide patients with access to a new therapeutic option in clinical trials.
How similar studies have gone: While the production of cGMP capsules is a standard practice, the specific application of ATTM in clinical trials is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
-
Irisys, INC.
San Diego, United States Active
Researchers
- Principal investigator: Giannini, Robert — Irisys, INC.
- Study coordinator: Giannini, Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.